The Effect of Intravenous Tranexamic Acid in Percutaneous Renal Biopsy: A Single Center, Triple-blinded, Randomized Controlled Trial
Not Applicable
- Conditions
- Pathological states in which percutaneous renal biopsy is indicated
- Registration Number
- JPRN-UMIN000019830
- Lead Sponsor
- Kyoto University
- Brief Summary
We assessed 90 adult patients for study eligibility, of whom, 56 were randomly allocated into the three groups: 20 for high-dose tranexamic acid, 19 for low-dose tranexamic acid, and 17 for placebo. The median size of perirenal hematoma was 200 mm2 [interquartile range 21-650] in the high-dose tranexamic acid group, 52 mm2 [0-139] in the low-dose tranexamic acid group, and 0 mm2 [0-339] in the placebo group (p = 0.048 for high-dose tranexamic acid vs. placebo).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
Not provided
Exclusion Criteria
- Those for whom amyloidosis is suspected - Those for whom tranexamic acid is contraindicated - Pregnant or breast-feeding women - Those who need tranexamic acid for treatment - Those who are judged to be unsuitable as research subjects by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Perirenal hematoma, measured by ultrasonography on the morning following the percutaneous renal biopsy
- Secondary Outcome Measures
Name Time Method